Zogenix Painkiller Fails to Win Support of U.S. Advisers

By Anna Edney Zogenix Inc. (ZGNX)’s pure hydrocodone painkiller Zohydro failed to win the backing of U.S. advisers, who said regulators should first take a closer look at measures ...

This Undervalued Pharma Is Ready To Move Higher

By Jordo Bivona Recently, AstraZeneca (NYSE: AZN), together with Bristol-Myers Squibb (NYSE: BMY)announced that the European Commission has approved Forxiga (dapagliflozin) ...

EU Upholds $63 Million Fine for AstraZeneca

By WILLIAM DOTINGA (CN) – Europe’s highest court upheld a $63 million fine against pharmaceutical giant AstraZeneca for blocking the generic version of its Losec ulcer medication ...

This Metric Says You’re Smart to Own Impax Laboratories

By Seth Jayson There’s no foolproof way to know the future for Impax Laboratories (Nasdaq: IPXL  ) or any other company. However, certain clues may help you see potential ...

The Revolution of The Pharma Industry

By Michael Nolan It is the lesser known of the current “cliffs,” however, to some, it’s just as important. It’s called “the patent cliff,” and it’s turning the pharmaceutical ...

Pfizer markets $ billion revolving credit to back spinoff

By Michelle Sierra (Reuters) – Pfizer Inc (PFE.N) is in market with a $1 billion, five-year revolver that will back the company’s spinoff of its animal health division, ...

How AstraZeneca Has Fared During 2012

By Sonia Rehill LONDON — AstraZeneca  (LSE: AZN  ) (NYSE: AZN  ) has gained 0.13% to 2,982 pence so far during 2012, making the share one of the year’s less exciting ...

Controversial FDA Official Tom Laughren Retires

By Ed Silverman  One of the more controversial figures at the FDA over the past decade quietly retired late last month. Tom Laughren, who was the director of the Division of Psychiatry ...

And The Worst Biotech CEO Of The Year Is…

By Ed Silverman  There is nothing like a drop in stock price to upset investors and employees who are counting on a biotech ceo to deliver the goods and make everyone not only rich, ...

No Gold In Those Pfizer Labs: $700,000 Goes Missing

By Ed Silverman  As Pfizer looks to cut millions of dollars in expenses, one way that ceo Ian Read can save money is to ask the folks who run the labs not to leave gold dust lying ...

FDA wants PMA, not 510(k), for Abiomed’s Impella

By Damian Garde An FDA panel voted to keep temporary ventricular support devices such as Abiomed’s ($ABMD) Impella under the Class III device designation, which, under a ...

Medtronic pays dividend early to beat possible tax changes

By Damian Garde With the looming fiscal cliff, it’s anyone’s guess how taxes on dividends may change come 2013, so Medtronic ($MDT) is serving up a Christmas gift to its ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS